NeoGenomics Q3 revenue beats estimates on higher-value cancer testing; raises FY2026 outlook
NEO•NeoGenomics reported Q3 revenue of $209 million, slightly above the $207.33 million estimate, and adjusted net income of $10.5 million. It raised its 2026 revenue guidance to $807 million-$809 million and expects adjusted EBITDA of about $60 million.
1. Quarterly results
NeoGenomics' Q3 revenue rose 11% year over year to $209 million, slightly above analyst estimates of $207.33 million. Adjusted net income was $10.5 million, compared with $4 million a year earlier, while the company reported a net loss of $7.5 million.
2. Raised outlook
The company raised its 2026 revenue guidance to $807 million-$809 million and expects adjusted EBITDA of approximately $60 million. It forecast a 2026 net loss of $30 million-$32 million. Clinical services revenue growth was driven by a 29% increase in next-generation sequencing revenue, and average revenue per clinical test rose 11% to $530.
